Page 1

EX - 99.1 2 d245311dex991.htm EX - 99.1 amedisys Exhibit 99.1 AMEDISYS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS UPDATES 2021 GUIDANCE BATON ROUGE , Louisiana ( November 2 , 2021 ) — Amedisys , Inc. ( NASDAQ : AMED ) today reported its financial results for the three and nine- month periods ended September 30 , 2021 . Three - Month Periods Ended September 30 , 2021 and 2020 • Net service revenue increased $ 9.4 million to $ 553.5 million compared to $ 544.1 million in 2020 . • Net income attributable to Amedisys , Inc. of $ 45.0 million compared to $ 72.0 million ( inclusive of a $ 24.0 million income tax benefit related to executive stock option exercise ) in 2020 . Net income attributable to Amedisys , Inc. per diluted share of $ 1.37 compared to $ 2.16 ( inclusive of $ 0.72 income tax benefit related to executive stock option exercise ) in 2020 . Adjusted Quarterly Results * • Adjusted EBITDA of $ 72.4 million compared to $ 75.7 million in 2020 . Adjusted net service revenue of $ 553.5 million compared to $ 544.1 million in 2020 . Adjusted net income attributable to Amedisys , Inc. of $ 50.5 million compared to $ 74.6 million ( inclusive of a $ 24.0 million income tax benefit related to executive stock option exercise ) in 2020 . Adjusted net income attributable to Amedisys , Inc. per diluted share of $ 1.53 compared to $ 2.24 ( inclusive of $ 0.72 income tax benefit related to executive stock option exercise ) in 2020 . Nine - Month Periods Ended September 30 , 2021 and 2020 • • Net service revenue increased $ 134.0 million to $ 1,654.8 million compared to $ 1,520.8 million in 2020 . Net income attributable to Amedisys , Inc. of $ 175.0 million compared to $ 138.5 million ( inclusive of a $ 24.0 million income tax benefit related to executive stock option exercise ) in 2020 . Net income attributable to Amedisys , Inc. per diluted share of $ 5.30 compared to $ 4.16 ( inclusive of $ 0.72 income tax benefit related to executive stock option exercise ) in 2020 . Adjusted Year to Date Results * * Adjusted EBITDA of $ 234.8 million compared to $ 195.4 million in 2020 . • Adjusted net service revenue of $ 1,648.3 million compared to $ 1,520.8 million in 2020 . • Adjusted net income attributable to Amedisys , Inc. of $ 157.5 million compared to $ 153.9 million ( inclusive of a $ 24.0 million income tax benefit related to executive stock option exercise ) in 2020 . Adjusted net income attributable to Amedisys , Inc. per diluted share of $ 4.77 compared to $ 4.63 ( inclusive of $ 0.72 income tax benefit related to executive stock option exercise ) in 2020 . See pages 3 and 16 - 18 for the definition and reconciliations of non - GAAP financial measures to GAAP measures . 1